Anti-interferon-gamma monoclonal antibody (DrugBank: -)
1 disease告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
96 | クローン病 | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00072943 (ClinicalTrials.gov) | March 2002 | 12/11/2003 | A Humanized Anti-Interferon-? Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease | A Phase II, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of a Humanized Anti-Interferon-? Monoclonal Antibody (HuZAF) Administered to Patients With Moderate to Severe Crohn's Disease | Crohn's Disease;Colitis;Intestinal Disease;Gastrointestinal Disease;Digestive System Disease | Drug: anti-Interferon-gamma monoclonal antibody | Facet Biotech | NULL | Completed | 18 Years | 70 Years | Both | 175 | Phase 2 | United States;Canada |